CSTL has 36-month beta value of 1.04. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CSTL is 27.94M, and currently, short sellers hold a 4.50% ratio of that float. The average trading volume of CSTL on June 19, 2025 was 430.14K shares.
CSTL) stock’s latest price update
The stock price of Castle Biosciences Inc (NASDAQ: CSTL) has surged by 2.00 when compared to previous closing price of 18.54, but the company has seen a 2.55% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-16 that FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase’s Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis (AD).
CSTL’s Market Performance
CSTL’s stock has risen by 2.55% in the past week, with a monthly rise of 15.30% and a quarterly drop of -7.94%. The volatility ratio for the week is 2.97% while the volatility levels for the last 30 days are 2.14% for Castle Biosciences Inc The simple moving average for the past 20 days is 9.46% for CSTL’s stock, with a -25.42% simple moving average for the past 200 days.
Analysts’ Opinion of CSTL
Many brokerage firms have already submitted their reports for CSTL stocks, with Guggenheim repeating the rating for CSTL by listing it as a “Buy.” The predicted price for CSTL in the upcoming period, according to Guggenheim is $25 based on the research report published on December 14, 2023 of the previous year 2023.
Scotiabank, on the other hand, stated in their research note that they expect to see CSTL reach a price target of $54. The rating they have provided for CSTL stocks is “Sector Outperform” according to the report published on January 05th, 2023.
Stephens gave a rating of “Overweight” to CSTL, setting the target price at $59 in the report published on January 07th of the previous year.
CSTL Trading at 3.39% from the 50-Day Moving Average
After a stumble in the market that brought CSTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.24% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CSTL starting from MAETZOLD DEREK J, who sale 4,408 shares at the price of $21.52 back on Apr 21 ’25. After this action, MAETZOLD DEREK J now owns 4,275 shares of Castle Biosciences Inc, valued at $94,851 using the latest closing price.
MAETZOLD DEREK J, the Pres. & Chief Exec. Officer of Castle Biosciences Inc, sale 1,236 shares at $21.52 during a trade that took place back on Apr 21 ’25, which means that MAETZOLD DEREK J is holding 74,627 shares at $26,596 based on the most recent closing price.
Stock Fundamentals for CSTL
Current profitability levels for the company are sitting at:
- -0.04 for the present operating margin
- 0.86 for the gross margin
The net margin for Castle Biosciences Inc stands at -0.01. The total capital return value is set at -0.03. Equity return is now at value -1.20, with -1.06 for asset returns.
Based on Castle Biosciences Inc (CSTL), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 2.54. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -25.25.
Currently, EBITDA for the company is 38.14 million with net debt to EBITDA at -1.71. When we switch over and look at the enterprise to sales, we see a ratio of 1.39. The receivables turnover for the company is 6.16for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.37.
Conclusion
To put it simply, Castle Biosciences Inc (CSTL) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
